These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 16258103

  • 21. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
    Bauer R, Wild PJ, Meyer S, Bataille F, Pauer A, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff AK.
    J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
    [Abstract] [Full Text] [Related]

  • 22. Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness.
    Moretti S, Spallanzani A, Chiarugi A, Fabiani M, Pinzi C.
    J Am Acad Dermatol; 2001 Feb; 44(2):188-92. PubMed ID: 11174375
    [Abstract] [Full Text] [Related]

  • 23. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
    Vitoux D, Mourah S, Kerob D, Verola O, Basset-Seguin N, Baccard M, Schartz N, Ollivaud L, Archimbaud A, Servant JM, Revol M, Toubert ME, Podgorniak MP, Plassa F, Porcher R, Lebbé C.
    Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
    [Abstract] [Full Text] [Related]

  • 24. Significance of cell kinetic parameters in the prognosis of malignant melanoma: a review.
    Vereecken P, Laporte M, Heenen M.
    J Cutan Pathol; 2007 Feb; 34(2):139-45. PubMed ID: 17244025
    [Abstract] [Full Text] [Related]

  • 25. Gene expression profiling of primary cutaneous melanoma.
    Winnepenninckx V, Van den Oord JJ.
    Verh K Acad Geneeskd Belg; 2007 Feb; 69(1):23-45. PubMed ID: 17427873
    [Abstract] [Full Text] [Related]

  • 26. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit.
    McKinnon JG, Yu XQ, McCarthy WH, Thompson JF.
    Cancer; 2003 Sep 15; 98(6):1223-31. PubMed ID: 12973846
    [Abstract] [Full Text] [Related]

  • 27. Novel role for RGS1 in melanoma progression.
    Rangel J, Nosrati M, Leong SP, Haqq C, Miller JR, Sagebiel RW, Kashani-Sabet M.
    Am J Surg Pathol; 2008 Aug 15; 32(8):1207-12. PubMed ID: 18580492
    [Abstract] [Full Text] [Related]

  • 28. PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs.
    Roels S, Tilmant K, Ducatelle R.
    J Comp Pathol; 1999 Jul 15; 121(1):13-24. PubMed ID: 10373290
    [Abstract] [Full Text] [Related]

  • 29. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.
    Francken AB, Shaw HM, Thompson JF, Soong SJ, Accortt NA, Azzola MF, Scolyer RA, Milton GW, McCarthy WH, Colman MH, McGovern VJ.
    Ann Surg Oncol; 2004 Apr 15; 11(4):426-33. PubMed ID: 15070604
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors.
    Lindholm C, Andersson R, Dufmats M, Hansson J, Ingvar C, Möller T, Sjödin H, Stierner U, Wagenius G, Swedish Melanoma Study Group.
    Cancer; 2004 Nov 01; 101(9):2067-78. PubMed ID: 15372475
    [Abstract] [Full Text] [Related]

  • 32. Predictors of regional nodal disease in patients with thin melanomas.
    Karakousis GC, Gimotty PA, Botbyl JD, Kesmodel SB, Elder DE, Elenitsas R, Ming ME, Guerry D, Fraker DL, Czerniecki BJ, Spitz FR.
    Ann Surg Oncol; 2006 Apr 01; 13(4):533-41. PubMed ID: 16523360
    [Abstract] [Full Text] [Related]

  • 33. Prognostic models in melanoma.
    Halpern AC, Schuchter LM.
    Semin Oncol; 1997 Feb 01; 24(1 Suppl 4):S2-7. PubMed ID: 9122730
    [Abstract] [Full Text] [Related]

  • 34. Primary dermal melanoma: distinct immunohistochemical findings and clinical outcome compared with nodular and metastatic melanoma.
    Cassarino DS, Cabral ES, Kartha RV, Swetter SM.
    Arch Dermatol; 2008 Jan 01; 144(1):49-56. PubMed ID: 18209168
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma.
    Thies A, Schachner M, Berger J, Moll I, Schulze HJ, Brunner G, Schumacher U.
    J Pathol; 2004 Aug 01; 203(4):933-9. PubMed ID: 15258996
    [Abstract] [Full Text] [Related]

  • 37. Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group.
    Cook MG, Spatz A, Bröcker EB, Ruiter DJ.
    J Pathol; 2002 Jun 01; 197(2):188-93. PubMed ID: 12015742
    [Abstract] [Full Text] [Related]

  • 38. Apolipoprotein D expression in cutaneous malignant melanoma.
    Miranda E, Vizoso F, Martín A, Quintela I, Corte MD, Seguí ME, Ordiz I, Merino AM.
    J Surg Oncol; 2003 Jun 01; 83(2):99-105. PubMed ID: 12772203
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR, El-Zammar O.
    Am J Dermatopathol; 2008 Apr 01; 30(2):117-22. PubMed ID: 18360113
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.